Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Philadelphia, 132 South 10th Street, 1170 Main, Philadelphia, PA 19107, USA.
Biomark Med. 2013 Feb;7(1):23-35. doi: 10.2217/bmm.12.110.
Throughout the last century medical advances in cancer treatment in the fields of surgery, radiation therapy and chemotherapy have greatly impacted patients' survival rates. Nevertheless, cancer remains a significant cause of mortality, with an estimated 7.6 million deaths worldwide in 2008, reflecting the inability of existing therapies to effectively cure disease. The emergence of vaccines and their successes in preventing the spread of infectious diseases has demonstrated the unique specificity and therapeutic potential of the immune system. This potential has driven the development of novel cancer immunotherapeutics. This review focuses on the current status of the use of immunologic effectors to target known biomarkers in cancer.
在过去的一个世纪中，癌症治疗领域在手术、放射治疗和化疗方面的医学进展极大地影响了患者的生存率。然而，癌症仍然是一个主要的死亡原因，据估计，2008 年全球有 760 万人死亡，这反映了现有疗法无法有效地治愈疾病。疫苗的出现及其在预防传染病传播方面的成功表明了免疫系统的独特特异性和治疗潜力。这一潜力推动了新型癌症免疫疗法的发展。本综述重点介绍了利用免疫效应物针对癌症已知生物标志物的当前应用状况。
